Boston Scientific (BSX) traded lower on April 27, 2026, as the market continued to digest the company’s Q1 earnings update from April 22 that included a reduced full-year 2026 outlook. While Q1 sales and adjusted EPS came in around (or slightly above) expectations, investor focus has remained on the reset in growth expectations and the areas of the portfolio management flagged as pressured, keeping near-term sentiment cautious. (news.bostonscientific.com)

With its Q1 release, Boston Scientific guided to full-year 2026 adjusted EPS of about $3.34 to $3.41 and organic net sales growth of about 6.5% to 8.0%, a step down from its earlier 2026 framework. The company attributed the reset to “unanticipated headwinds,” and market commentary around the print highlighted softer WATCHMAN trends alongside issues in urology and cardiac rhythm management that could weigh most heavily in the first half of 2026. (news.bostonscientific.com)

After the Q1 report, multiple analysts cut price targets even while maintaining generally positive ratings, reinforcing the message that near-term execution has become more important to the equity story. In that context, incremental down days like April 27 can reflect position adjustments and recalibration of valuation multiples rather than a single new headline. (streetinsider.com)